NASDAQ:FREQ

Frequency Therapeutics (FREQ) Stock Forecast, Price & News

$0.39

+0.02 (+5.95%)

(As of 09:54 AM ET)

Compare

Today's Range: $0.37
▼
$0.41
50-Day Range: $0.36
▼
$0.73
52-Week Range: $0.33
▼
$5.59

Volume: 22,556 shs
Average Volume: 906,619 shs
Market Capitalization: $14.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.33

Frequency Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 1,568.4% Upside
$6.33 Price Target
Short Interest: Healthy
1.54% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.07
Based on 7 Articles This Week
Insider Trading: Selling Shares
$36,103 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.70) to ($1.45) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

468th out of 969 stocks

Pharmaceutical Preparations Industry

213th out of 454 stocks

3.0

Analyst's Opinion

Consensus Rating
Frequency Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.33, Frequency Therapeutics has a forecasted upside of 1,568.4% from its current price of $0.38.
Amount of Analyst Coverage
Frequency Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.54% of the float of Frequency Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Frequency Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Frequency Therapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Frequency Therapeutics does not currently pay a dividend.
Dividend Growth
Frequency Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FREQ.

1.6

News and Social Media Coverage

News Sentiment
Frequency Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Frequency Therapeutics this week, compared to 1 article on an average week.
Search Interest
12 people have searched for FREQ on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Frequency Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Frequency Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,103.00 in company stock.
Percentage Held by Insiders
16.80% of the stock of Frequency Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.18% of the stock of Frequency Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Frequency Therapeutics are expected to grow in the coming year, from ($1.70) to ($1.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Frequency Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Frequency Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Frequency Therapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Frequency Therapeutics (NASDAQ:FREQ) Stock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

FREQ Price History

30 days | 90 days | 365 days | Advanced Chart

FREQ Stock News Headlines

September 28, 2023 | businesswire.com

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

September 27, 2023 | msn.com

Baird Downgrades Frequency Therapeutics (FREQ)

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

September 27, 2023 | americanbankingnews.com

Frequency Therapeutics (NASDAQ:FREQ) Stock Rating Lowered by Robert W. Baird

September 26, 2023 | markets.businessinsider.com

Hold Rating on Frequency Therapeutics Amidst Pending Merger and Financing Developments

September 25, 2023 | benzinga.com

Zucara Therapeutics Doses First Patient in Phase 2a 'ZONE' Trial

September 24, 2023 | yahoo.com

If you have recurring nightmares, therapy can help you prevent and rewrite them to get a good night's sleep

August 18, 2023 | thestreet.com

Frequency Therapeutics Inc.

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

August 10, 2023 | finance.yahoo.com

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

July 28, 2023 | fool.com

Frequency Therapeutics (NASDAQ: FREQ)

July 17, 2023 | msn.com

Frequency (FREQ) Up 77% on Merger Deal With Korro Bio

July 14, 2023 | benzinga.com

FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders

July 14, 2023 | msn.com

Korro Bio absorbs Frequency Therapeutics in reverse biotech merger

July 14, 2023 | finance.yahoo.com

Why Are Frequency Therapeutics Shares Surging Today

July 14, 2023 | markets.businessinsider.com

Korro Bio, Frequency Therapeutics Sign All-stock Merger Deal

July 14, 2023 | seekingalpha.com

Frequency Therapeutics jumps on all-stock merger with Korro Bio

July 14, 2023 | marketwatch.com

Frequency Therapeutics Shares Soar Premarket on Reverse Merger Deal >FREQ

July 14, 2023 | finance.yahoo.com

Korro Bio and Frequency Therapeutics Announce Merger Agreement

July 14, 2023 | finance.yahoo.com

Korro Bio and Frequency Therapeutics Announce Merger Agreement

July 14, 2023 | investorplace.com

Why Is Frequency Therapeutics (FREQ) Stock Up 44% Today?

July 6, 2023 | msn.com

Best home radio frequency device for skin tightening

June 21, 2023 | finance.yahoo.com

FREQ - Frequency Therapeutics, Inc.

June 7, 2023 | msn.com

Frequency Therapeutics to reduce workforce by ~55%

May 12, 2023 | msn.com

Frequency Therapeutics: Q1 Earnings Insights

May 12, 2023 | msn.com

Frequency Therapeutics GAAP EPS of -$0.55 misses by $0.11

May 12, 2023 | finance.yahoo.com

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

See More Headlines

Receive FREQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FREQ Company Calendar

Last Earnings: 8/10/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FREQ
CUSIP: N/A
CIK: 1703647
Web: www.frequencytx.com
Phone: 781-315-4600
Fax: N/A
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.33
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +1,611.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-81,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -107.67%
Return on Assets: -61.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.81
Quick Ratio: 5.81

Sales & Book Value

Annual Sales: $14.07 million
Price / Sales: 0.96
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.96 per share
Price / Book: 0.19

Miscellaneous

Outstanding Shares: 36,520,000
Free Float: 30,385,000
Market Cap: $13.51 million
Optionable: Not Optionable
Beta: 0.77

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. David L. Lucchino (Age 53)
Co-Founder, Pres, CEO & Director
Comp: $1.02M

Mr. Richard J. Mitrano (Age 52)
VP of Fin. & Operations

Mr. James P. Abely
Associate Gen. Counsel & Sec.

Dr. John L. LaMattina Ph.D. (Age 73)
Sr. Advisor & Member of PCA Regenerative Medicine Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FREQ Stock - Frequently Asked Questions

Should I buy or sell Frequency Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares.
View FREQ analyst ratings or view top-rated stocks.
What is Frequency Therapeutics' stock price forecast for 2023?: 5 brokers have issued 12 month target prices for Frequency Therapeutics' stock. Their FREQ share price forecasts range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 1,611.7% from the stock's current price.
View analysts price targets for FREQ or view top-rated stocks among Wall Street analysts.
How have FREQ shares performed in 2023?: Frequency Therapeutics' stock was trading at $3.85 at the beginning of the year. Since then, FREQ stock has decreased by 90.4% and is now trading at $0.37.
View the best growth stocks for 2023 here.
When is Frequency Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our FREQ earnings forecast.
How were Frequency Therapeutics' earnings last quarter?: Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.14.
What other stocks do shareholders of Frequency Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

When did Frequency Therapeutics IPO?: (FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.
What is Frequency Therapeutics' stock symbol?: Frequency Therapeutics trades on the NASDAQ under the ticker symbol "FREQ."
How do I buy shares of Frequency Therapeutics?: Shares of FREQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Frequency Therapeutics' stock price today?: One share of FREQ stock can currently be purchased for approximately $0.37.
How much money does Frequency Therapeutics make?: Frequency Therapeutics (NASDAQ:FREQ) has a market capitalization of $13.51 million and generates $14.07 million in revenue each year. The company earns $-81,580,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.
How can I contact Frequency Therapeutics?: Frequency Therapeutics' mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The official website for the company is www.frequencytx.com. The company can be reached via phone at 781-315-4600 or via email at investorrelations@frequencytx.com.

This page (NASDAQ:FREQ) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Frequency Therapeutics (FREQ) Stock Forecast, Price & News

Frequency Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Frequency Therapeutics (NASDAQ:FREQ) Stock

FREQ Price History

FREQ Stock News Headlines

FREQ Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FREQ Stock - Frequently Asked Questions

Overall MarketRank^™